374 related articles for article (PubMed ID: 27107440)
21. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
22. Exosomes as Biomarkers of Human and Feline Mammary Tumours; A Comparative Medicine Approach to Unravelling the Aggressiveness of TNBC.
Howard J; Wyse C; Argyle D; Quinn C; Kelly P; McCann A
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188431. PubMed ID: 32950643
[TBL] [Abstract][Full Text] [Related]
23. Classification and gene selection of triple-negative breast cancer subtype embedding gene connectivity matrix in deep neural network.
Liu J; Su R; Zhang J; Wei L
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33415328
[TBL] [Abstract][Full Text] [Related]
24. Genetics of triple-negative breast cancer: Implications for patient care.
Afghahi A; Telli ML; Kurian AW
Curr Probl Cancer; 2016; 40(2-4):130-140. PubMed ID: 28340968
[TBL] [Abstract][Full Text] [Related]
25. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
26. A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer.
Vitali F; Cohen LD; Demartini A; Amato A; Eterno V; Zambelli A; Bellazzi R
PLoS One; 2016; 11(9):e0162407. PubMed ID: 27632168
[TBL] [Abstract][Full Text] [Related]
27. Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways.
Karagoz K; Sinha R; Arga KY
OMICS; 2015 Feb; 19(2):115-30. PubMed ID: 25611337
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
Tseng LM; Chiu JH; Liu CY; Tsai YF; Wang YL; Yang CW; Shyr YM
Breast Cancer Res Treat; 2017 Jun; 163(2):241-254. PubMed ID: 28299476
[TBL] [Abstract][Full Text] [Related]
31. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
[TBL] [Abstract][Full Text] [Related]
32. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
33. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
34. Chk1 as a new therapeutic target in triple-negative breast cancer.
Albiges L; Goubar A; Scott V; Vicier C; Lefèbvre C; Alsafadi S; Commo F; Saghatchian M; Lazar V; Dessen P; Delaloge S; André F; Quidville V
Breast; 2014 Jun; 23(3):250-8. PubMed ID: 24636978
[TBL] [Abstract][Full Text] [Related]
35. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
36. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.
Makvandi M; Tilahun ED; Lieberman BP; Anderson RC; Zeng C; Xu K; Hou C; McDonald ES; Pryma DA; Mach RH
Biochem Biophys Res Commun; 2015 Nov; 467(4):1070-5. PubMed ID: 26453012
[TBL] [Abstract][Full Text] [Related]
37. Identification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway Analysis.
Wu T; Wang X; Li J; Song X; Wang Y; Wang Y; Zhang L; Li Z; Tian J
PLoS One; 2015; 10(6):e0131183. PubMed ID: 26126114
[TBL] [Abstract][Full Text] [Related]
38. Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification.
Marotti JD; de Abreu FB; Wells WA; Tsongalis GJ
Am J Pathol; 2017 Oct; 187(10):2133-2138. PubMed ID: 28734944
[TBL] [Abstract][Full Text] [Related]
39. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
40. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
